In Brief: Urohealth
This article was originally published in The Gray Sheet
Urohealth: Receives conditional IDE approval from FDA for clinical trials of RelaX, a valved intraurethral catheter for the management of female incontinence. The device is designed to be left within the urethra for 29 days. Urohealth claims that possible advantages of the Relax over similar devices such as UroMed's Reliance include decreased risk of infection, convenience and "ease of use." Unlike the Reliance, the Relax can be used during sexual intercourse, the company adds. Relax is priced "competitively" at approximately $110 a month or $1200-1500 a year. The conditional IDE approval allows the company "to begin filing for investigational review board (IRB) approvals at designated clinical sites around the country and to begin clinical trials as the IRBs approvals are granted." The company plans on conducting clinical trials with approximately 130 patients at up to 12 sites...
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.